Histone deacetylase inhibitors and HIV latency.
OBJECTIVE
Interest has re-emerged in approaches to eradicate HIV infection. A series of modifications of nucleosomal histones within chromatin are a key mechanism of HIV gene regulation that alters the recruitment of transcription factors to viral DNA. The balance of these histone modifications in the vicinity of the HIV LTR plays an important role in the maintenance of proviral quiescence in rare latently infected cells, and presents a target for therapies aimed at purging this reservoir of persistent HIV infection.


RESULTS
Altering the balance of acetylase and deacetylase activity within CD4+ lymphocytes using histone deacetylase (HDAC) inhibitors, or other epigenetic drugs, has recently emerged as a promising approach to purge the reservoir of persistent infection. Multiple molecular mechanisms appear to underlie the establishment and maintenance of persistent, latent HIV infection, most frequently in the resting central memory CD4+ T cell. HDAC inhibitors perturb this balance, induce expression of integrated provirus, and may allow attack of this primary form of persistent HIV infection.


CONCLUSIONS
Although HDAC inhibitors are a promising approach, a better understanding of relevant mechanisms of latency in vivo, and better tools to translate this knowledge into therapies are needed.
Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. dmargo@med.unc.edu
David M
DM
Margolis
D019380:Anti-HIV Agents / Q000378:metabolism; D006678:HIV / Q000472:pathogenicity*; D015658:HIV Infections / Q000821:virology*; D056572:Histone Deacetylase Inhibitors / Q000378:metabolism*; D054884:Host-Pathogen Interactions; D006801:Humans; D017735:Virus Latency / Q000187:drug effects*
D019380:Anti-HIV Agents; D056572:Histone Deacetylase Inhibitors
EMBO J. 2007 Jan 24;26(2):412-23
17245431
Genes Dev. 1997 Dec 15;11(24):3327-40
9407026
PLoS One. 2010 Feb 23;5(2):e9390
20186346
Cell. 1986 Apr 11;45(1):95-104
3955658
AIDS. 2008 Jun 19;22(10):1125-9
18525257
PLoS Pathog. 2009 Aug;5(8):e1000554
19696893
EMBO J. 1993 Aug;12(8):3249-59
8344262
J Biol Chem. 2009 Mar 13;284(11):6782-9
19136668
J Virol. 2010 Jun;84(12):5958-74
20357084
Virology. 2010 Sep 15;405(1):234-42
20594570
Science. 2001 Aug 10;293(5532):1074-80
11498575
Virology. 1993 Oct;196(2):496-505
8372431
Genes Dev. 2001 Nov 1;15(21):2786-96
11691830
Curr HIV/AIDS Rep. 2010 Feb;7(1):37-43
20425056
J Biol Chem. 2006 May 5;281(18):12495-505
16540471
EMBO J. 2003 Dec 15;22(24):6550-61
14657027
AIDS Res Hum Retroviruses. 2009 Sep;25(9):883-7
19689202
PLoS Pathog. 2009 Jun;5(6):e1000495
19557157
Retrovirology. 2009 Jun 02;6:52
19486542
EMBO J. 2003 Apr 15;22(8):1868-77
12682019
Curr HIV Res. 2010 Sep;8(6):418-29
20636281
J Virol. 2000 Aug;74(15):6790-9
10888618
J Acquir Immune Defic Syndr. 2010 May 1;54(1):1-9
20300007
J Virol. 1991 Dec;65(12):6790-9
1942252
Lancet. 2005 Aug 13-19;366(9485):549-55
16099290
Nat Rev Mol Cell Biol. 2003 Apr;4(4):276-84
12671650
J Infect Dis. 2007 Mar 15;195(6):833-6
17299713
J Virol. 2007 Oct;81(20):10914-23
17670825
AIDS Res Hum Retroviruses. 2009 Feb;25(2):207-12
19239360
AIDS. 2004 May 21;18(8):1101-8
15166525
PLoS One. 2009 Jun 30;4(6):e6093
19564922
EMBO J. 2006 Jan 11;25(1):139-49
16319923
AIDS. 2008 Jun 19;22(10):1131-5
18525258
EMBO J. 1996 Mar 1;15(5):1112-20
8605881
Biochem Biophys Res Commun. 1987 Nov 13;148(3):899-905
2825693
EMBO J. 2007 Dec 12;26(24):4985-95
18007589
J Virol. 2009 May;83(10):4749-56
19279091
Int J Mol Med. 2010 Aug;26(2):265-72
20596607
AIDS. 2009 Sep 10;23(14):1799-806
19590405